Down modulation of IL‐18 expression by human papillomavirus type 16 E6 oncogene via binding to IL‐18

Cho, Young Sik; Kang, Jeong Woo; Cho, Min Chul; Cho, Cheong-Weon; Lee, Shin Je; Choe, Yong Kyung; Kim, Yong Man; Choi, In Pyo; Park, Sue Nie; Kim, Soo Hyun; Dinarello, Charles A.; Yoon, Do Young

doi:10.1016/s0014-5793(01)02652-7

Cited by 89 publications

(67 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…An E6 oncoprotein-mediated reduction in expressed interleukin-8 (IL-18) CD8 + was also observed [60].…”

Section: Humoral Immune Responses and Cell-mediated Immune Responses mentioning

confidence: 96%

“…The lipid core peptide (LCP), a vaccine delivery system incorporating lipoamino acids, was used to produce vaccine candidates against HPV-16 [104]. Moyle et al demonstrated that an LCP system that incorporated the long sequence E7 [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] (known as 8Q) with CTL, T helper cell, and B cell epitopes was self-adjuvanting and reduced tumor size. This epitope was unable to prevent TC-1 tumors when delivered alone [104].…”

Section: Vaccine Deliverymentioning

confidence: 99%

“…The self-adjuvanting properties of LCP are predominantly derived from its propensity to target vaccines to DCs and induce DC maturation [22,112]. In another mouse study, a lipopeptide vaccine incorporated the E6 [43][44][45][46][47][48][49][50][51][52][53][54][55][56][57] and E7 [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] epitopes conjugated to a dipalmitoyl-lysine-glycineglycine (Pam 2 KGG) moiety. It was shown that although both epitopes were individually able to elicit specific CTL responses in mice, the lipid-tailed (Pam 2 KGG) diepitopic construct was more efficient than the monomeric forms [113].…”

Section: Vaccine Deliverymentioning

confidence: 99%

“…Another animal study, which used a long peptide (E7 [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] ) and the DC-activating adjuvant ODN-CpG, has identified that vaccination with a longer peptide containing CTL and Th cell epitopes, and ODN-CpG represents a promising strategy against MHC-I deficient tumors. This study also investigated the efficacy of cellular vaccines based on ex vivo cultured DCs pulsed with either minimal CTL (E7 [49][50][51][52][53][54][55][56][57] ) epitope or longer CTL (E7 [44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] ) epitopes, and then matured with ODNCpG. The use of ex vivo cultured DCs is particularly suitable f...…”

Section: Vaccine Deliverymentioning

confidence: 99%

“…Intratumoral administration with E7 peptide in combination with PADRE and poly(I:C) generated better CD8 + T cell immune responses when compared with subcutaneous vaccination [123]. Combining a long CTL (E [43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62] ) epitope with poly(I:C) and the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA), has also been shown to enhance the E7 specific CD8 + T cell immune responses. Interestingly, the timing/treatment regimen of DMXAA administration played an important role in vaccine efficacy [124].…”

Section: Vaccine Deliverymentioning

confidence: 99%

See 4 more Smart Citations

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

Liu¹,

Hussein²,

Tóth³

et al. 2012

CTMC

View full text Add to dashboard Cite

Cervical cancer is the second leading cause of cancer in women worldwide. Human papillomavirus (HPV) is responsible for all cases of cervical cancer. Commercial prophylactic HPV vaccines are now available, but unfortunately these vaccines have no therapeutic effect against established HPV infections. In order to accelerate the control of cervical cancer and treat established HPV infections, it is necessary to develop therapeutic vaccines to eradicate HPV by generating cell-mediated immunity against HPV infected cells. Two HPV-encoded early proteins, the E6 and E7 oncoproteins, are the preferred targets because they are consistently expressed in virtually all cervical cancer cells and are necessary for the induction and maintenance of HPV-associated disease. A variety of vaccine strategies have been employed targeting immune responses to these proteins. Peptide-based vaccines are a promising strategy for the development of therapeutic HPV vaccines because of their safety, stability, and ease of production. This review summarizes the prospects of peptidebased vaccines for the treatment of established HPV infections. We address the challenges that scientists currently face for developing peptide-based vaccines and explore feasible strategies for improving the potency of the induced immune response with the aim of treating established HPV infections.

show abstract

“…An E6 oncoprotein-mediated reduction in expressed interleukin-8 (IL-18) CD8 + was also observed [60].…”

Section: Humoral Immune Responses and Cell-mediated Immune Responses mentioning

confidence: 96%

Section: Vaccine Deliverymentioning

confidence: 99%

Section: Vaccine Deliverymentioning

confidence: 99%

Section: Vaccine Deliverymentioning

confidence: 99%

Section: Vaccine Deliverymentioning

confidence: 99%

See 3 more Smart Citations

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

Liu¹,

Hussein²,

Tóth³

et al. 2012

CTMC

View full text Add to dashboard Cite

show abstract

IL‐18, but not IL‐12, is required for optimal cytokine production by influenza virus‐specific CD8⁺ T cells

et al. 2007

View full text Add to dashboard Cite

The potent innate cytokines IL-12 and IL-18 are considered to be important antigenindependent mediators of IFN-c production by NK cells and T lymphocytes. The present analysis addresses the physiological role of IL-12 and IL-18 in the generation of virusspecific CD8 + T cells. Both wt C57BL/6J (B6) mice and mice with disrupted IL-12p40 (IL-12p40 -/-) or IL-18 (IL-18 -/-) genes were infected with an influenza A virus and the characteristics of the resultant epitope-specific CD8 + T cell responses were compared. While IL-12 appeared to have no notable effect on either virus growth or on CD8 + T cell response profiles, the absence of IL-18 was associated with delayed virus clearance from the lung and, despite normal numbers, a significantly reduced production of IFN-c, TNF-a, and IL-2 by epitope-specific CD8 + T cells. While this cytokine phenotype was broadly maintained in IL-12p40/IL-18 double-knockout mice, no evidence was seen for any additive effect. Together, our results suggest that IL-18, but not IL-12, induces optimal, antigen-specific production of key cytokines by CD8 + T cells for the efficient clearance of influenza virus from the lungs of infected mice.

show abstract

Genome‐wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray

Wong

Cheung

Tsao

et al. 2006

Intl Journal of Cancer

107

View full text Add to dashboard Cite

An analysis of gene expression profiles obtained from cervical cancers was performed to find those genes most aberrantly expressed. Total RNA was prepared from 29 samples of cervical squamous cell carcinoma and 18 control samples, and hybridized to Affymetrix oligonucleotide microarrays with probe sets complementary to over 20,000 transcripts. Unsupervised hierarchical clustering of the expression data readily distinguished normal cervix from cancer. Supervised analysis of gene expression data identified 98 and 139 genes that exhibited >2-fold upregulation and >2-fold downregulation, respectively, in cervical cancer compared to normal cervix. Several of the genes that were differentially regulated included SPP1 (Osteopontin), CDKN2A (p16), RPL39L, Clorf1, MAL, p11, ARS and NICE-1. These were validated by quantitative RT-PCR on an independent set of cancer and control specimens. Gene Ontology analysis showed that the list of differentially expressed genes included ones that were involved in multiple biological processes, including cell proliferation, cell cycle and protein catabolism. Immunohistochemical staining of cancer specimens further confirmed differential expression of SPP1 in cervical cancer cells vs. nontumor cells. In addition, 2 genes, CTGF and RGS1 were found to be upregulated in late stage cancer compared to early stage cancer, suggesting that they might be involved in cancer progression. The pathway analysis of expression data showed that the SPP1, VEGF, CDC2 and CKS2 genes were coordinately differentially regulated between cancer and normal. The present study is promising and provides potential new insights into the extent of expression differences underlying the development and progression of cervical squamous cell cancer. This study has also revealed several genes that may be highly attractive candidate molecular markers/targets for cervical cancer diagnosis, prognosis and therapy. ' 2005 Wiley-Liss, Inc.

show abstract

Down modulation of IL‐18 expression by human papillomavirus type 16 E6 oncogene via binding to IL‐18

Cited by 89 publications

References 50 publications

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

IL‐18, but not IL‐12, is required for optimal cytokine production by influenza virus‐specific CD8⁺ T cells

Genome‐wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray

Contact Info

Product

Resources

About

Down modulation of IL‐18 expression by human papillomavirus type 16 E6 oncogene via binding to IL‐18

Cited by 89 publications

References 50 publications

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

Advances in Peptide-based Human Papillomavirus Therapeutic Vaccines

IL‐18, but not IL‐12, is required for optimal cytokine production by influenza virus‐specific CD8+ T cells

Genome‐wide gene expression profiling of cervical cancer in Hong Kong women by oligonucleotide microarray

Contact Info

Product

Resources

About

IL‐18, but not IL‐12, is required for optimal cytokine production by influenza virus‐specific CD8⁺ T cells